Halozyme Therapeutics | HALO - Current Assets


Halozyme Therapeutics reported $1B in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.1B 33.9M Mar/2026
Agios Pharmaceuticals USD 834.84M 107.21M Mar/2026
Alnylam Pharmaceuticals USD 4.22B 168.65M Mar/2026
Amarin USD 626.02M 23.87M Mar/2026
Amgen USD 31.48B 2.42B Mar/2026
Baxter International USD 6.85B 25M Mar/2026
Cara Therapeutics USD 31.54M 6.9M Dec/2025
Cytokinetics USD 839.46M 77.51M Mar/2026
DBV Technologies USD 212.94M 124.06M Dec/2025
Eli Lilly USD 54.84B 794M Mar/2026
Esperion Therapeutics USD 459.46M 3.11M Mar/2026
Halozyme Therapeutics USD 1B 177.83M Mar/2026
Intrexon USD 23.72M 45.04M Jun/2024
Ionis Pharmaceuticals USD 2.94B 52M Mar/2026
MannKind USD 251.16M 40.42M Mar/2026
Minerva Neurosciences USD 83.1M 70.08M Dec/2025
Nektar Therapeutics USD 266.27M 15.09M Dec/2025
Pfizer USD 42.82B 76M Mar/2026
Rigel Pharmaceuticals USD 214.93M 39.53M Sep/2025
United Therapeutics USD 2.87B 830.5M Mar/2026
Vanda Pharmaceuticals USD 347.26M 20.23M Dec/2025